ASCENDIS PHARMA A/S - ADR (ASND)
US04351P1012 - ADR
Overall ASND gets a fundamental rating of 2 out of 10. We evaluated ASND against 572 industry peers in the Biotechnology industry. ASND may be in some trouble as it scores bad on both profitability and health. ASND is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year ASND has reported negative net income.
ASND had a negative operating cash flow in the past year.
In the past 5 years ASND always reported negative net income.
In the past 5 years ASND always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -38.99%, ASND perfoms like the industry average, outperforming 57.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-49.06%
ROA(5y)-44.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASND has a Gross Margin of 84.82%. This is amongst the best in the industry. ASND outperforms 88.50% of its industry peers.
ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASND has more shares outstanding
The number of shares outstanding for ASND has been increased compared to 5 years ago.
The debt/assets ratio for ASND is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.10, we must say that ASND is in the distress zone and has some risk of bankruptcy.
ASND's Altman-Z score of 0.10 is fine compared to the rest of the industry. ASND outperforms 64.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.1 |
ROIC/WACCN/A
WACC6.56%
2.3 Liquidity
A Current Ratio of 1.16 indicates that ASND should not have too much problems paying its short term obligations.
The Current ratio of ASND (1.16) is worse than 85.84% of its industry peers.
ASND has a Quick Ratio of 1.16. This is a bad value and indicates that ASND is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.84, ASND is doing worse than 89.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
ASND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.32%, which is quite impressive.
ASND shows a strong growth in Revenue. In the last year, the Revenue has grown by 115.53%.
ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.68% yearly.
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.28%
Revenue 1Y (TTM)115.53%
Revenue growth 3Y237.31%
Revenue growth 5Y90.68%
Sales Q2Q%20.4%
3.2 Future
ASND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.57% yearly.
The Revenue is expected to grow by 56.76% on average over the next years. This is a very strong growth
EPS Next Y13.09%
EPS Next 2Y22.53%
EPS Next 3Y25.58%
EPS Next 5Y31.57%
Revenue Next Year31.71%
Revenue Next 2Y54.41%
Revenue Next 3Y66.12%
Revenue Next 5Y56.76%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASND. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASND's earnings are expected to grow with 25.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.53%
EPS Next 3Y25.58%
5. Dividend
5.1 Amount
ASND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASCENDIS PHARMA A/S - ADR
NASDAQ:ASND (1/15/2025, 9:40:35 AM)
133.59
+2.02 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.12%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner ChangeN/A
Market Cap7.99B
Analysts87.62
Price Target199.24 (49.14%)
Short Float %5.77%
Short Ratio7.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.17%
Min EPS beat(2)-35.43%
Max EPS beat(2)3.09%
EPS beat(4)2
Avg EPS beat(4)-14.23%
Min EPS beat(4)-50.09%
Max EPS beat(4)25.51%
EPS beat(8)4
Avg EPS beat(8)-9%
EPS beat(12)6
Avg EPS beat(12)-3.75%
EPS beat(16)8
Avg EPS beat(16)-3.26%
Revenue beat(2)0
Avg Revenue beat(2)-44.57%
Min Revenue beat(2)-57.97%
Max Revenue beat(2)-31.16%
Revenue beat(4)2
Avg Revenue beat(4)10.75%
Min Revenue beat(4)-57.97%
Max Revenue beat(4)113.87%
Revenue beat(8)5
Avg Revenue beat(8)16.43%
Revenue beat(12)9
Avg Revenue beat(12)27.34%
Revenue beat(16)10
Avg Revenue beat(16)13.3%
PT rev (1m)1.17%
PT rev (3m)-1.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-119.72%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-17.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.58%
Revenue NY rev (1m)2.26%
Revenue NY rev (3m)-5.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 23.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.65
EYN/A
EPS(NY)-4.37
Fwd EYN/A
FCF(TTM)-4.5
FCFYN/A
OCF(TTM)-4.48
OCFYN/A
SpS5.61
BVpS-1.67
TBVpS-1.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.99% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.82% | ||
| FCFM | N/A |
ROA(3y)-49.06%
ROA(5y)-44.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.39% | ||
| Cap/Sales | 0.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 0.1 |
F-Score5
WACC6.56%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)111.23%
Cap/Sales(3y)113.56%
Cap/Sales(5y)137.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.28%
EPS Next Y13.09%
EPS Next 2Y22.53%
EPS Next 3Y25.58%
EPS Next 5Y31.57%
Revenue 1Y (TTM)115.53%
Revenue growth 3Y237.31%
Revenue growth 5Y90.68%
Sales Q2Q%20.4%
Revenue Next Year31.71%
Revenue Next 2Y54.41%
Revenue Next 3Y66.12%
Revenue Next 5Y56.76%
EBIT growth 1Y44.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.3%
EBIT Next 3Y32.99%
EBIT Next 5YN/A
FCF growth 1Y46.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.22%
OCF growth 3YN/A
OCF growth 5YN/A